156 related articles for article (PubMed ID: 15194554)
21. Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia.
Papayannidis C; Derenzini E; Iacobucci I; Curti A; Paolini S; Cilloni D; Baccarani M; Martinelli G
Am J Hematol; 2009 Dec; 84(12):849-50. PubMed ID: 19844989
[No Abstract] [Full Text] [Related]
22. Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin.
Asano H; Yamamoto G; Hosoi M; Takahashi T; Hangaishi A; Kurokawa M
Leuk Res; 2010 Jul; 34(7):e152-3. PubMed ID: 20061019
[No Abstract] [Full Text] [Related]
23. Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy.
Boyiadzis M; Redner RL; Raptis A; Hou JZ; Agha M; Foon KA
Ann Hematol; 2011 Jun; 90(6):733-5. PubMed ID: 20857113
[No Abstract] [Full Text] [Related]
24. Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed/refractory acute myeloid leukemia.
Bayraktar UD; Domingo GC; Schmit J; Pereira D
Leuk Lymphoma; 2011 May; 52(5):913-5. PubMed ID: 21417821
[No Abstract] [Full Text] [Related]
25. Gemtuzumab ozogamicin: time to resurrect?
Ravandi F; Estey EH; Appelbaum FR; Lo-Coco F; Schiffer CA; Larson RA; Burnett AK; Kantarjian HM
J Clin Oncol; 2012 Nov; 30(32):3921-3. PubMed ID: 22987091
[No Abstract] [Full Text] [Related]
26. Complete remission induced by gemtuzumab ozogamicin in a Jehovah's Witness patient with acute myelogenous leukemia.
Fujisawa S; Naito K; Matsuoka T; Kobayashi M
Int J Hematol; 2007 Jun; 85(5):418-20. PubMed ID: 17562618
[TBL] [Abstract][Full Text] [Related]
27. Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.
Fianchi L; Pagano L; Leoni F; Storti S; Voso MT; Valentini CG; Rutella S; Scardocci A; Caira M; Gianfaldoni G; Leone G
Ann Oncol; 2008 Jan; 19(1):128-34. PubMed ID: 17906298
[TBL] [Abstract][Full Text] [Related]
28. Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukemia.
Filanovsky K; Shvidel L; Shtalrid M
J Clin Oncol; 2010 Mar; 28(7):e115-6; author reply e117-8. PubMed ID: 20100951
[No Abstract] [Full Text] [Related]
29. Gemtuzumab ozogamicin: one size does not fit all--the case for personalized therapy.
Ravandi F
J Clin Oncol; 2011 Feb; 29(4):349-51. PubMed ID: 21172885
[No Abstract] [Full Text] [Related]
30. Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients.
Pirrotta MT; Bocchia M; Bucalossi A; Defina M; Forconi F; Gozzetti A; Lauria F
Acta Haematol; 2007; 118(1):7-9. PubMed ID: 17389781
[No Abstract] [Full Text] [Related]
31. A comparative evaluation of gemtuzumab ozogamicin + daunorubicin-cytarabine and other treatments for newly diagnosed acute myeloid leukemia.
Ashaye AO; Khankhel Z; Xu Y; Fahrbach K; Mokgokong R; Orme ME; Lang K; Cappelleri JC; Mamolo C
Future Oncol; 2019 Feb; 15(6):663-681. PubMed ID: 30450960
[TBL] [Abstract][Full Text] [Related]
32. First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients.
Piccaluga PP; Martinelli G; Rondoni M; Malagola M; Gaitani S; Visani G; Baccarani M
Leuk Res; 2004 Sep; 28(9):987-90. PubMed ID: 15234577
[TBL] [Abstract][Full Text] [Related]
33. Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia.
Oshikawa G; Kakihana K; Saito M; Aoki J; Najima Y; Kobayashi T; Doki N; Sakamaki H; Ohashi K
Br J Haematol; 2015 Jun; 169(5):756-9. PubMed ID: 25522128
[No Abstract] [Full Text] [Related]
34. Trying to improve clinical outcome in AML: lessons from negative trials.
Karp JE; Smith BD
Leuk Res; 2005 Jun; 29(6):603-4. PubMed ID: 15863196
[No Abstract] [Full Text] [Related]
35. Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML).
Middeldorf I; Galm O; Osieka R; Jost E; Herman JG; Wilop S
Am J Hematol; 2010 Jul; 85(7):477-81. PubMed ID: 20575043
[TBL] [Abstract][Full Text] [Related]
36. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Tsimberidou A; Estey E; Cortes J; Thomas D; Faderl S; Verstovsek S; Garcia-Manero G; Keating M; Albitar M; O'Brien S; Kantarjian H; Giles F
Cancer; 2003 Mar; 97(6):1481-7. PubMed ID: 12627513
[TBL] [Abstract][Full Text] [Related]
37. Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older.
Eom KS; Kim HJ; Min WS; Lee S; Min CK; Cho BS; Kim SY; Kim YJ; Lee DG; Choi SM; Cho SG; Kim DW; Lee JW; Shin WS; Kim CC
Eur J Haematol; 2007 Nov; 79(5):398-404. PubMed ID: 17916082
[TBL] [Abstract][Full Text] [Related]
38. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.
Walter RB; Medeiros BC; Gardner KM; Orlowski KF; Gallegos L; Scott BL; Hendrie PC; Estey EH
Haematologica; 2014 Jan; 99(1):54-9. PubMed ID: 24142996
[TBL] [Abstract][Full Text] [Related]
39. Remission induction in a Jehovah's witness patient with acute myeloid leukaemia using gemtuzumab ozogamicin.
Bareford D; Odeh B; Narayanan S; Wiltshire S
Transfus Med; 2005 Oct; 15(5):445-8. PubMed ID: 16202062
[TBL] [Abstract][Full Text] [Related]
40. Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia.
Bahashwan S; Moluçon-Chabrot C; Hermet E; Ravinet A; Douge A; Veronese L; Tchirkov A; Lemal R; Berger MG; Veyrat-Masson R; Tournilhac O; Bay JO; Guièze R
Am J Hematol; 2019 Jan; 94(1):E32-E35. PubMed ID: 30370957
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
